ABSTRACT
Considering the importance of dental health of patients' receiving dialysis and necessity of dentists and health officials' more attention to decisions and planning for such patients, this study aims to investigate the prevalence and status of tooth decay and gum diseases in dialysis patients in Red Crescent Center of Tehranpars. In this cross-sectional study, a total of 69 adult HD patients were evaluated in Red Crescent Center of Tehranpars by sampling in 2006. Data was collected through observation; interview and examination. The dental health status of patients was undertaken, in addition to their clinical and demographic characteristic.According to the results, the mean [SD] of DMF was 17/2 +/- 9/9 in all cases and were 11/44 +/- 2/6 in dentate ones; the mean of NIDCR was 34/5 +/- 25/4; also%45/8 of edentulous patients used of prosthetic devices at night; 54/2% of edentulous patients had mobility prosthesis in the lower jaw; 37/5% of the edentulous patients were with denture stomatitis lesions in the upper jaw. Regarding the furcation-involved teeth 41/5% and 26/8% of respondents had grade I and II respectively. Statistically, there was no significant correlation between furcation-involvement and duration of dialysis [P=0.654]. Given the dental plaque, 11/1% of patients had no calculus, 88/9% and 62/2% of participants had sub gingival calculus and supra gingival calculus respectively. About a third, brush their teeth sometimes or infrequently; and a half of the respondents brush their teeth horizontally. At the end, no significant correlation was observed between DS in upper jaw and using of prosthetic devices at night. Due to antibacterial properties of saliva urea in these patients, kidney disease and dialysis has no effect on tooth decay and will not exacerbate the disease. Therefore, it is necessary to do further studies comprehensively regarding dietary and drug regimens
ABSTRACT
PDpoietin is a recombinant erythropoietin alfa that has been introduced by a manufacturer in Iran. We assessed the effectiveness and complications of PDpoietin in comparison with Eprex in anemic patients on hemodialysis. This clinical trial was performed in a multicenter setting. Patients with a hemoglobin level less than 12 g/dL were assigned into 2 groups in order to receive either Eprex [Janssen Cilag] or PDpoietin [Pooyesh Darou] for 3 months. Forty-one and 34 patients completed the study in the PDpoietin and Eprex groups, respectively. The mean hemoglobin levels at baseline were not significantly different between the two groups of patients with PDpoietin and Eprex. In both groups, hemoglobin levels increased significantly, but there were no significant differences between the two groups at months 1, 2, and 3. At the end of the study, the mean hemoglobin levels reached 11.6 +/- 1.7 g/dL and 11.8 +/- 1.9 g/dL, respectively [P = .002; P = .01]. The mean hemoglobin per cumulative of drug dose index [hemoglobin/[erythropoietin dose/1000 x injections per month]] was not significantly different between the two groups at different treatment stages, and it did not change significantly in each group during the course of the study. No serious complications were reported. Eprex and PDpoietin could equally increase the hemoglobin levels with no significant complication. Therefore, PDpoietin can be used for treatment of anemia in patients on dialysis, and the patients will have the advantages of its availability and low price